Juvederm

Allergan Launches JUVEDERM Lips Consumer Campaign

Juvederm

Allergan is launching a new direct-to-consumer campaign for JUVÉDERM Lips. Centered around self-expression, the campaign kicks off on February 11 with ads and creative deploying across TV, social media and digital advertising. Board-certified plastic surgeon Dara Liotta, MD, reality television personality Audrina Patridge and celebrity makeup artist Kelsey Deenihan will share how and why they choose JUVÉDERM as their lip filler brand of choice.

Allergan Launches Juvéderm Volite

Allergan has launched Juvéderm Volite, a hyaluronic-based injectable filler specifically designed to improve skin quality in the face, neck, décolletage and hands. Volite uses patented Vycross technology and is formulated to last up to nine months with a single treatment session. It should be injected intradermally and contains lidocaine for patient comfort.

JUVÉDERM VOLBELLA XC Approved for Lips and Perioral Rhytides

JUVÉDERM VOLBELLA XC Approved for Lips and Perioral Rhytides

Allergan has received U.S. Food and Drug Administration (FDA) approval to market JUVÉDERM VOLBELLA XC for lip augmentation and correction of perioral rhytides in adults over the age of 21. The filler is formulated with Allergan’s proprietary VYCROSS technology, which blends different molecular weights of hyaluronic acid (HA) for a longer-lasting results. It also features a lower HA concentration (15mg/mL), making it a appropriate for adding subtle volume to the lips and softening the appearance of perioral lines.

Voluma XC Satisfactory Results Last up to Two Years

Voluma XC Satisfactory Results Last up to Two Years

A multicenter, single-blind randomized, controlled study to examine the efficacy of Juvéderm Voluma XC—an HA filler for the correction of midface volume deficit (MVD)—from the patients’ perspectives has shown high patient satisfaction up to two years following treatment. The study, conducted by Julius Few, MD, et al, included subjects treated at 15 sites in the U.S. and Canada from August 2009 to June 2012.

JUVEDERM VOLUMA XC Gains Favorable Review on Path to Approval

JUVEDERM VOLUMA XC Gains Favorable Review on Path to Approval

The U.S. Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee has voted unanimously that the benefits of JUVEDERM VOLUMA XC—an injectable hyaluronic acid volume filler—outweigh the risks. The committee's recommendation, although not binding, will be considered by the FDA when making the final approval decision for JUVEDERM VOLUMA XC for cheek augmentation to correct age-related volume deficit in the mid-face. If approved by the FDA, Allergan anticipates launching the new filler in late 2013.